Actinium Pharmaceuticals to Present ATNM-400 Efficacy in Breast Cancer at SABCS 2026#USA#San_Antonio#SABCS#Actinium#ATNM-400
Actinium Pharmaceuticals to Present ATNM-400 Efficacy in Breast Cancer at SABCS 2026
Actinium Pharmaceuticals will showcase ATNM-400's preclinical efficacy in therapy-resistant breast cancer at the upcoming SABCS 2026, emphasizing its potential across various cancers.
third-news.com
November 2, 2026 at 1:18 PM
Actinium Pharmaceuticals to Present ATNM-400 Efficacy in Breast Cancer at SABCS 2026#USA#San_Antonio#SABCS#Actinium#ATNM-400
Kazia Therapeutics to Present Innovations in Tumor Reprogramming at SABCS 2026#USA#San_Antonio#Kazia_Therapeutics#Paxalisib#SABCS_2026
Kazia Therapeutics to Present Innovations in Tumor Reprogramming at SABCS 2026
Kazia Therapeutics has announced the acceptance of two abstracts focusing on paxalisib's unique tumor reprogramming mechanisms for presentation at the 2026 SABCS.
third-news.com
November 2, 2026 at 12:25 PM
Kazia Therapeutics to Present Innovations in Tumor Reprogramming at SABCS 2026#USA#San_Antonio#Kazia_Therapeutics#Paxalisib#SABCS_2026
#ATNM Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Ac…
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-announces-acceptance-of-atnm-400-abstract-u5lvkksgfj30.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-announces-acceptance-of-atnm-400-abstract-u5lvkksgfj30.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 1:00 PM
#ATNM Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Ac…
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-announces-acceptance-of-atnm-400-abstract-u5lvkksgfj30.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-announces-acceptance-of-atnm-400-abstract-u5lvkksgfj30.html?utm_source=stocktitan-bluesky&utm_medium=social
Bio-Rad has expanded its precision oncology research portfolio, including new Droplet Digital™ PCR assays, reagents and technologies to support oncology research applications.
The Company will showcase its new portfolio at AMP 2026 and SABCS.
Read more here: rebrand.ly/4hhceuy
The Company will showcase its new portfolio at AMP 2026 and SABCS.
Read more here: rebrand.ly/4hhceuy
November 3, 2026 at 3:52 PM
Bio-Rad has expanded its precision oncology research portfolio, including new Droplet Digital™ PCR assays, reagents and technologies to support oncology research applications.
The Company will showcase its new portfolio at AMP 2026 and SABCS.
Read more here: rebrand.ly/4hhceuy
The Company will showcase its new portfolio at AMP 2026 and SABCS.
Read more here: rebrand.ly/4hhceuy
Actinium Pharma announces acceptance of #$ATNM 400 abstract @ San Antonio Breast Cancer Symposium
*8-11 Dec
*Poster to highlight preclinical efficacy across therapy-resistant breast cancer subtypes
ir.actiniumpharma.com/press-releas...
*8-11 Dec
*Poster to highlight preclinical efficacy across therapy-resistant breast cancer subtypes
ir.actiniumpharma.com/press-releas...
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models :: Actinium Pharmaceuticals, Inc. ...
ir.actiniumpharma.com
November 4, 2026 at 6:21 PM
Actinium Pharma announces acceptance of #$ATNM 400 abstract @ San Antonio Breast Cancer Symposium
*8-11 Dec
*Poster to highlight preclinical efficacy across therapy-resistant breast cancer subtypes
ir.actiniumpharma.com/press-releas...
*8-11 Dec
*Poster to highlight preclinical efficacy across therapy-resistant breast cancer subtypes
ir.actiniumpharma.com/press-releas...
Congratulations Dr. Perou www.aacr.org/about-the-aa...
Charles M. Perou, PhD, FAACR, Honored With 2026 William L. McGuire Memorial Lecture Award
SAN ANTONIO – Charles M. Perou, PhD, Fellow of the AACR Academy, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium 2026 (SABCS), to be held Dece...
www.aacr.org
October 21, 2026 at 3:41 PM
Congratulations Dr. Perou www.aacr.org/about-the-aa...
What does the latest research tell us about multimodal AI in breast cancer?
This #BreastCancerAwarenessMonth, explore findings on risk stratification and chemotherapy benefit in early-stage disease.
▪️ ASCO 2026: buff.ly/E3nQcvw
▪️ SABCS 2025: buff.ly/Rpcez3X
This #BreastCancerAwarenessMonth, explore findings on risk stratification and chemotherapy benefit in early-stage disease.
▪️ ASCO 2026: buff.ly/E3nQcvw
▪️ SABCS 2025: buff.ly/Rpcez3X
October 15, 2026 at 8:03 PM
What does the latest research tell us about multimodal AI in breast cancer?
This #BreastCancerAwarenessMonth, explore findings on risk stratification and chemotherapy benefit in early-stage disease.
▪️ ASCO 2026: buff.ly/E3nQcvw
▪️ SABCS 2025: buff.ly/Rpcez3X
This #BreastCancerAwarenessMonth, explore findings on risk stratification and chemotherapy benefit in early-stage disease.
▪️ ASCO 2026: buff.ly/E3nQcvw
▪️ SABCS 2025: buff.ly/Rpcez3X
This approval was based on results from the HER2CLIMB-05 trial, which were presented at the San Antonio Breast Cancer Symposium 2025. Learn more about this trial and the history of tucatinib as a treatment for breast cancer on the AACRBlog: buff.ly/LURJt1a
Tracking the History of Tucatinib for Breast Cancer Treatment at SABCS
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
buff.ly
October 7, 2026 at 6:07 PM
This approval was based on results from the HER2CLIMB-05 trial, which were presented at the San Antonio Breast Cancer Symposium 2025. Learn more about this trial and the history of tucatinib as a treatment for breast cancer on the AACRBlog: buff.ly/LURJt1a
“The science we bring forward is at the heart of this symposium.”
Two days remain to submit late-breaking abstracts to #SABCS26. Program Director Kate Lathrop, MD, discusses how researchers can still contribute to the global scientific conversation in SABCS Meeting News: https://bit.ly/4xIVBEA
Two days remain to submit late-breaking abstracts to #SABCS26. Program Director Kate Lathrop, MD, discusses how researchers can still contribute to the global scientific conversation in SABCS Meeting News: https://bit.ly/4xIVBEA
September 28, 2026 at 2:19 PM
“The science we bring forward is at the heart of this symposium.”
Two days remain to submit late-breaking abstracts to #SABCS26. Program Director Kate Lathrop, MD, discusses how researchers can still contribute to the global scientific conversation in SABCS Meeting News: https://bit.ly/4xIVBEA
Two days remain to submit late-breaking abstracts to #SABCS26. Program Director Kate Lathrop, MD, discusses how researchers can still contribute to the global scientific conversation in SABCS Meeting News: https://bit.ly/4xIVBEA
When should endocrine therapy change for patients with HR-positive metastatic breast cancer? Drs. Virginia Kaklamani, Erika Hamilton and Komal Jhaveri discuss SERENA-4, SERENA-6 and imlunestrant + abemaciclib in this SABCS Snippet. #SABCS26. Watch: https://youtu.be/-wsO5LQXJgE
SABCS Snippets - SERENA-4, SERENA-6 and the timing of endocrine therapy - September 18, 2026
YouTube video by San Antonio Breast Cancer Symposium
youtu.be
September 19, 2026 at 12:40 PM
When should endocrine therapy change for patients with HR-positive metastatic breast cancer? Drs. Virginia Kaklamani, Erika Hamilton and Komal Jhaveri discuss SERENA-4, SERENA-6 and imlunestrant + abemaciclib in this SABCS Snippet. #SABCS26. Watch: https://youtu.be/-wsO5LQXJgE
Learn more about imlunestrant, which is a type of therapy known as a selective estrogen receptor degrader (SERD), as well as other kinds of molecular degraders on the #AACRBlog: buff.ly/OelCIPv
Please SERD, I Want Some More (Molecular Degraders)
A session on molecular degraders at SABCS 2024 highlighted an exciting new frontier for SERDs, PROTACs, LYTACs, and biparatopic antibodies.
buff.ly
September 18, 2026 at 8:27 PM
Learn more about imlunestrant, which is a type of therapy known as a selective estrogen receptor degrader (SERD), as well as other kinds of molecular degraders on the #AACRBlog: buff.ly/OelCIPv
In this SABCS® Snippet, Kate I. Lathrop, MD, William Gradishar, MD, and Seth Wander, MD join patient advocate Julia Maués to discuss camizestrant’s accelerated FDA approval and what the findings could mean for patients and clinical practice. #SABCS
https://www.youtube.com/watch?v=BKf0AMbyo3I
https://www.youtube.com/watch?v=BKf0AMbyo3I
SABCS Snippets – FDA Approval of Camizestrant – September 4, 2026
YouTube video by San Antonio Breast Cancer Symposium
www.youtube.com
September 10, 2026 at 12:17 AM
In this SABCS® Snippet, Kate I. Lathrop, MD, William Gradishar, MD, and Seth Wander, MD join patient advocate Julia Maués to discuss camizestrant’s accelerated FDA approval and what the findings could mean for patients and clinical practice. #SABCS
https://www.youtube.com/watch?v=BKf0AMbyo3I
https://www.youtube.com/watch?v=BKf0AMbyo3I
The SABCS community mourns the loss of Sandi Stanford, a pioneer in patient advocacy, a fierce leader, mentor and friend to so many. Her impact on the breast cancer community is immeasurable. She will be deeply missed.
Share your photos and memories of Sandi in the comments.
Share your photos and memories of Sandi in the comments.
September 3, 2026 at 10:15 PM
The SABCS community mourns the loss of Sandi Stanford, a pioneer in patient advocacy, a fierce leader, mentor and friend to so many. Her impact on the breast cancer community is immeasurable. She will be deeply missed.
Share your photos and memories of Sandi in the comments.
Share your photos and memories of Sandi in the comments.
Dear Colleagues,
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
December 8, 2025 at 12:55 PM
Dear Colleagues,
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
An Honor for OncoAlert 🚨 To announce that our Special Collaboration with SABCS continues for the 3rd Year Running! Welcome to the Alamo City for what is always OUR Home Coming for The OncoAlert Network, the San Antonio Breast Cancer Symposium #SABCS25 #BreastCancer
See Y'all Real Soon
The Network
See Y'all Real Soon
The Network
December 4, 2025 at 2:06 PM
An Honor for OncoAlert 🚨 To announce that our Special Collaboration with SABCS continues for the 3rd Year Running! Welcome to the Alamo City for what is always OUR Home Coming for The OncoAlert Network, the San Antonio Breast Cancer Symposium #SABCS25 #BreastCancer
See Y'all Real Soon
The Network
See Y'all Real Soon
The Network
Visit our collaborators at @vjoncology.bsky.social for the expert breakdowns of the science out of SABCS 2024. Providing the latest trial data and expert insights on #BreastCancer and beyond.
Follow them at
https://bit.ly/48P9tCd
Follow them at
https://bit.ly/48P9tCd
December 23, 2024 at 2:48 PM
Visit our collaborators at @vjoncology.bsky.social for the expert breakdowns of the science out of SABCS 2024. Providing the latest trial data and expert insights on #BreastCancer and beyond.
Follow them at
https://bit.ly/48P9tCd
Follow them at
https://bit.ly/48P9tCd
Risk-reducing mastectomy & salpingo-oophorectomy significantly improve OS, disease-free survival, and breast cancer-free interval in young BRCA+ #BreastCancer patients, with a greater impact of RRSO seen in BRCA1 carriers.
Report with Shani Paluch-Shimon (high5 Onc)
Report with Shani Paluch-Shimon (high5 Onc)
High5 Oncology TV: SABCS 2024
72 videos online
buff.ly
December 19, 2024 at 7:13 PM
Risk-reducing mastectomy & salpingo-oophorectomy significantly improve OS, disease-free survival, and breast cancer-free interval in young BRCA+ #BreastCancer patients, with a greater impact of RRSO seen in BRCA1 carriers.
Report with Shani Paluch-Shimon (high5 Onc)
Report with Shani Paluch-Shimon (high5 Onc)
PADMA presented at #SABCS24 showed that palbociclib + ET improves time to treatment failure and PFS compared to chemotherapy in high-risk HR+/HER2- metastatic breast cancer, supporting use as the standard 1st L tx
Report with Alessandra Gennari (high5 Onc)
Report with Alessandra Gennari (high5 Onc)
High5 Oncology TV: SABCS 2024
61/ 64 videos online
buff.ly
December 17, 2024 at 2:00 PM
PADMA presented at #SABCS24 showed that palbociclib + ET improves time to treatment failure and PFS compared to chemotherapy in high-risk HR+/HER2- metastatic breast cancer, supporting use as the standard 1st L tx
Report with Alessandra Gennari (high5 Onc)
Report with Alessandra Gennari (high5 Onc)
Visit our collaborators at VJOncology for the expert breakdowns of the science out of SABCS 2024. Providing the latest trial data and expert insights on breast cancer and beyond.
Follow them at
https://bit.ly/48P9tCd
Follow them at
https://bit.ly/48P9tCd
December 17, 2024 at 12:22 PM
Visit our collaborators at VJOncology for the expert breakdowns of the science out of SABCS 2024. Providing the latest trial data and expert insights on breast cancer and beyond.
Follow them at
https://bit.ly/48P9tCd
Follow them at
https://bit.ly/48P9tCd
Join our collaborators at VJOncology during SABCS 2024, as they bring you the latest trial data and expert insights on breast cancer. Stay tuned for our comprehensive coverage of the event and get up to date through their Breast Cancer Channel
Follow them at
https://bit.ly/4fphtMY
Follow them at
https://bit.ly/4fphtMY
December 13, 2024 at 6:10 PM
Join our collaborators at VJOncology during SABCS 2024, as they bring you the latest trial data and expert insights on breast cancer. Stay tuned for our comprehensive coverage of the event and get up to date through their Breast Cancer Channel
Follow them at
https://bit.ly/4fphtMY
Follow them at
https://bit.ly/4fphtMY
An Amazing Day 3⃣ at #SABCS24 🇺🇸
Our gratitude to our hosts and Collaborators SABCS for their amazing work‼️
The Stats on X are:
✅54 million IMpressions
✅8,8k Posts
✅Around 1,5k Participants
WE ARE @OncoAlert 🚨
Our gratitude to our hosts and Collaborators SABCS for their amazing work‼️
The Stats on X are:
✅54 million IMpressions
✅8,8k Posts
✅Around 1,5k Participants
WE ARE @OncoAlert 🚨
December 13, 2024 at 4:34 AM
An Amazing Day 3⃣ at #SABCS24 🇺🇸
Our gratitude to our hosts and Collaborators SABCS for their amazing work‼️
The Stats on X are:
✅54 million IMpressions
✅8,8k Posts
✅Around 1,5k Participants
WE ARE @OncoAlert 🚨
Our gratitude to our hosts and Collaborators SABCS for their amazing work‼️
The Stats on X are:
✅54 million IMpressions
✅8,8k Posts
✅Around 1,5k Participants
WE ARE @OncoAlert 🚨
An Amazing Day 2⃣ at #SABCS24 🇺🇸
Our gratitude to our hosts and Collaborators at
@SABCS for their amazing work
The Stats on X are:
✅30 Million IMpressions
✅Close to 5,000 Posts
✅860 Participants
WE ARE @OncoAlert 🚨
Our gratitude to our hosts and Collaborators at
@SABCS for their amazing work
The Stats on X are:
✅30 Million IMpressions
✅Close to 5,000 Posts
✅860 Participants
WE ARE @OncoAlert 🚨
December 12, 2024 at 12:36 AM
An Amazing Day 2⃣ at #SABCS24 🇺🇸
Our gratitude to our hosts and Collaborators at
@SABCS for their amazing work
The Stats on X are:
✅30 Million IMpressions
✅Close to 5,000 Posts
✅860 Participants
WE ARE @OncoAlert 🚨
Our gratitude to our hosts and Collaborators at
@SABCS for their amazing work
The Stats on X are:
✅30 Million IMpressions
✅Close to 5,000 Posts
✅860 Participants
WE ARE @OncoAlert 🚨
Great overview of SABCS 2024 @sabcs.bsky.social by an incredible writer and advocate Diane Mapes @doublewhammied.bsky.social
www.fredhutch.org/en/news/cent...
www.fredhutch.org/en/news/cent...
What’s new in breast cancer research? SABCS24 looks at ctDNA, AI and ‘right-sizing’ treatment
More than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks and tools to take down b...
www.fredhutch.org
December 22, 2024 at 10:29 PM
Great overview of SABCS 2024 @sabcs.bsky.social by an incredible writer and advocate Diane Mapes @doublewhammied.bsky.social
www.fredhutch.org/en/news/cent...
www.fredhutch.org/en/news/cent...
Have you checked out our newest episode? In our "Report Back from SABCS" Dr. Bora Lim shares some of the notable highlights you need to stay informed & educated with what's new in #MetastaticBreastCancer treatment.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#BCSM #CanSky
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#BCSM #CanSky
March 20, 2026 at 1:19 PM
Have you checked out our newest episode? In our "Report Back from SABCS" Dr. Bora Lim shares some of the notable highlights you need to stay informed & educated with what's new in #MetastaticBreastCancer treatment.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#BCSM #CanSky
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#BCSM #CanSky
Dr. Lim from @utmdanderson.bsky.social discusses targeted therapy, ADC's moving to first line, emerging treatments for TNBC and more.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #SABCS #ClinicalTrials #BCSM #CanSky #podcast
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #SABCS #ClinicalTrials #BCSM #CanSky #podcast
March 18, 2026 at 1:08 PM
Dr. Lim from @utmdanderson.bsky.social discusses targeted therapy, ADC's moving to first line, emerging treatments for TNBC and more.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #SABCS #ClinicalTrials #BCSM #CanSky #podcast
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #SABCS #ClinicalTrials #BCSM #CanSky #podcast